Condition
Anaplastic Glioma
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results80% success
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (3)
Trial Status
Completed4
Withdrawn1
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04482933Phase 2Withdrawn
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
NCT00555399Phase 1Terminated
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
NCT01434602Phase 1Completed
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
NCT00009035Completed
Natural History of Patients With Brain and Spinal Cord Tumors
NCT00613093Phase 2Completed
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
NCT01200134Phase 2CompletedPrimary
HYPONCO - Hypoxia in Brain Tumors
Showing all 6 trials